Cowen and Company set a $40.00 target price on Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research note published on Thursday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the stock. ValuEngine raised shares of Heron Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, June 22nd. Cantor Fitzgerald reissued a buy rating and set a $31.00 target price (up from $30.00) on shares of Heron Therapeutics in a research report on Thursday, May 11th. Aegis reissued a buy rating and set a $33.00 target price on shares of Heron Therapeutics in a research report on Tuesday, July 18th. Jefferies Group LLC reissued a buy rating and set a $26.00 target price on shares of Heron Therapeutics in a research report on Friday, July 14th. Finally, Zacks Investment Research raised shares of Heron Therapeutics from a hold rating to a buy rating and set a $14.00 target price for the company in a research report on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $31.00.

Shares of Heron Therapeutics (NASDAQ HRTX) traded down 1.22% during midday trading on Thursday, reaching $16.15. 315,386 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $15.04 and a 200 day moving average price of $14.44. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $24.00.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The firm had revenue of $3.63 million for the quarter, compared to analysts’ expectations of $1.96 million. On average, equities research analysts expect that Heron Therapeutics will post ($3.72) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/04/heron-therapeutics-inc-hrtx-given-a-40-00-price-target-at-cowen-and-company.html.

Several hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc boosted its stake in shares of Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 2,383 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Heron Therapeutics by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after buying an additional 14,086 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Heron Therapeutics during the second quarter worth approximately $457,000. Rubric Capital Management LP boosted its stake in shares of Heron Therapeutics by 6.3% in the second quarter. Rubric Capital Management LP now owns 1,700,000 shares of the biotechnology company’s stock worth $23,545,000 after buying an additional 100,000 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Heron Therapeutics by 14.1% in the second quarter. Rhumbline Advisers now owns 50,630 shares of the biotechnology company’s stock worth $701,000 after buying an additional 6,249 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.